BTIG initiated coverage of Medline (MDLN) with a Buy rating and $50 price target The firm says the company is the “gold standard and leader” in medical surgical supply chain logistics. BTIG likes how Medline will be raising prices to address tariffs.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline initiated with an Outperform at Mizuho
- Medline: Durable Moat, Secular Tailwinds, and Attractive Valuation Support Buy Rating
- Medline: Durable Growth, Expanding Market Share, and Margin Upside Support Buy Rating and $46 Target
- Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward
- Medline, Inc. Class A: Leveraging a ‘Costco of Healthcare’ Model for Visible Growth, Margin Expansion, and Upside Potential